MarketCap
Facebook
X
Telegram
Sangamo Therapeutics ROCE Ratio | SGMO
Annual ROCE Ratio Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 849.73 | -456.61 | -330.58 | -68.24 | -48.85 | -16.3 | -18.53 | -15.07 | -23.3 | -50.18 | -23.77 | -11.94 | -20.39 | -30.1 | -44.7 | -44.6 | -27.03 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 849.73 | -456.61 | -22.38 |
Quarterly ROCE Ratio Sangamo Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1095.95 | -1237.32 | -824.37 | -824.17 | -299.12 | -379.17 | -217.26 | -144.14 | -79.64 | -40.28 | -45.66 | -57.58 | -50.76 | -46.24 | -32.71 | -33.45 | -29.13 | -27.13 | -17.29 | -24.05 | -31.05 | -33.59 | -24.66 | -29.09 | -27.55 | -25.53 | -15.38 | -22.32 | -24.68 | -28.4 | -22.67 | -36.77 | -49.54 | -54.99 | -46.06 | -52.65 | -44.93 | -28.45 | -16.2 | -19.91 | -16.73 | -14.03 | -10.8 | -15.86 | -16.65 | -18.91 | -15.23 | -24.17 | -27.96 | -34.69 | -29.01 | -40.96 | -44.85 | -47.98 | -36.76 | -11.95 | -12.83 | -11.98 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -10.8 | -1237.32 | -113.3 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
305.36 | $ 51.0 | 1.83 % | $ 1.48 B |  USA |
 |
Allakos
ALLK
|
-155.07 | - | - | $ 28.6 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
11.16 | $ 1.88 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
18.9 | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
2172.8 | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.73 | $ 60.26 | 0.06 % | $ 11.6 B | USA |
 |
BioNTech SE
BNTX
|
-7.08 | $ 98.52 | 0.24 % | $ 23.8 B |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.17 | 0.46 % | $ 3.57 M |  Israel |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-187.83 | - | - | $ 384 M |  Britain |
 |
Genocea Biosciences
GNCA
|
-192.4 | - | -15.0 % | $ 3.04 M | USA |
 |
Catalyst Biosciences
CBIO
|
10.83 | $ 13.99 | 0.84 % | $ 1.25 B | USA |
 |
C4 Therapeutics
CCCC
|
-44.91 | $ 2.98 | 0.3 % | $ 247 M | USA |
 |
Codexis
CDXS
|
-82.6 | $ 1.32 | 1.09 % | $ 115 M | USA |
 |
Amryt Pharma plc
AMYT
|
-5.86 | - | - | $ 621 M | Britain |
 |
Cerus Corporation
CERS
|
-13.52 | $ 2.62 | 0.38 % | $ 499 M | USA |
 |
G1 Therapeutics
GTHX
|
-111.7 | - | - | $ 370 M | USA |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.13 | 0.43 % | $ 132 M | USA |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 31.1 | 1.16 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-141.54 | $ 4.25 | 3.16 % | $ 51.9 M | Israel |
 |
Cellectar Biosciences
CLRB
|
-269.17 | $ 1.8 | 0.72 % | $ 4.69 M | USA |
 |
AbbVie
ABBV
|
-461.01 | $ 264.34 | 0.09 % | $ 468 B | USA |
 |
Humanigen
HGEN
|
146.06 | - | -81.12 % | $ 4.28 M | USA |
 |
Cocrystal Pharma
COCP
|
-120.22 | $ 1.17 | 1.74 % | $ 13.2 M | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 12.7 | 0.4 % | $ 3.79 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-56.18 | $ 5.4 | 2.65 % | $ 286 M | USA |
 |
Collegium Pharmaceutical
COLL
|
20.14 | $ 22.53 | 0.2 % | $ 713 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
6.92 | $ 116.1 | 4.93 % | $ 12.1 B | USA |
 |
Фармсинтез
LIFE
|
-4.03 | - | - | - |  Russia |
 |
IGM Biosciences
IGMS
|
-432.99 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-79.29 | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-76.05 | - | - | $ 123 M | USA |
 |
Cardiff Oncology
CRDF
|
-107.87 | $ 1.24 | 0.74 % | $ 82.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-57.84 | $ 7.14 | 0.19 % | $ 95.1 M | USA |
 |
Karuna Therapeutics
KRTX
|
-39.45 | - | - | $ 12.2 B | USA |
 |
Curis
CRIS
|
-104.6 | $ 0.83 | 1.1 % | $ 10.9 M | USA |
 |
CorMedix
CRMD
|
37.04 | $ 7.85 | 1.03 % | $ 565 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-34.58 | $ 54.23 | 0.23 % | $ 4.88 B |  Schweiz |
|
Champions Oncology
CSBR
|
-28.94 | $ 4.9 | 0.1 % | $ 67.8 M | USA |
 |
Chimerix
CMRX
|
-79.36 | - | - | $ 756 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-70.21 | $ 11.62 | 8.21 % | $ 918 M | USA |
 |
Cue Biopharma
CUE
|
-100.45 | $ 31.41 | 1.45 % | $ 2.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
-155.48 | $ 1.67 | 2.38 % | $ 13.4 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-49.83 | $ 4.85 | 0.2 % | $ 929 M | Canada |
 |
Cytokinetics, Incorporated
CYTK
|
92.82 | $ 64.66 | 0.17 % | $ 7.77 M | USA |
 |
Daré Bioscience
DARE
|
-476.75 | $ 0.78 | 4.73 % | $ 8.72 M | USA |
 |
Adagene
ADAG
|
-60.65 | $ 2.93 | 2.86 % | $ 173 M |  China |
 |
DiaMedica Therapeutics
DMAC
|
-61.16 | $ 7.94 | 1.4 % | $ 373 M | USA |